These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 27960172)

  • 1. Effect of AST-120 in Chronic Kidney Disease Treatment: Still a Controversy?
    Yamaguchi J; Tanaka T; Inagi R
    Nephron; 2017; 135(3):201-206. PubMed ID: 27960172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impacts of Indoxyl Sulfate and p-Cresol Sulfate on Chronic Kidney Disease and Mitigating Effects of AST-120.
    Liu WC; Tomino Y; Lu KC
    Toxins (Basel); 2018 Sep; 10(9):. PubMed ID: 30208594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of the efficacy of AST-120 (KREMEZIN
    Asai M; Kumakura S; Kikuchi M
    Ren Fail; 2019 Nov; 41(1):47-56. PubMed ID: 30732506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preventive effects of an oral sorbent on nephropathy in rats.
    Aoyama I; Miyazaki T; Niwa T
    Miner Electrolyte Metab; 1999; 25(4-6):365-72. PubMed ID: 10681668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of carbon adsorbent in the conservative management of chronic kidney disease.
    Niwa T
    Panminerva Med; 2017 Jun; 59(2):139-148. PubMed ID: 27990791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the Oral Adsorbent AST-120 on Organ-Specific Accumulation of Uremic Toxins: LC-MS/MS and MS Imaging Techniques.
    Sato E; Saigusa D; Mishima E; Uchida T; Miura D; Morikawa-Ichinose T; Kisu K; Sekimoto A; Saito R; Oe Y; Matsumoto Y; Tomioka Y; Mori T; Takahashi N; Sato H; Abe T; Niwa T; Ito S
    Toxins (Basel); 2017 Dec; 10(1):. PubMed ID: 29283413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting protein-bound uremic toxins in chronic kidney disease.
    Niwa T
    Expert Opin Ther Targets; 2013 Nov; 17(11):1287-301. PubMed ID: 23941498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of indoxyl sulfate in the progression of chronic kidney disease and cardiovascular disease: experimental and clinical effects of oral sorbent AST-120.
    Niwa T
    Ther Apher Dial; 2011 Apr; 15(2):120-4. PubMed ID: 21426500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indoxyl sulfate-lowering capacity of oral sorbents affects the prognosis of kidney function and oxidative stress in chronic kidney disease.
    Taki K; Niwa T
    J Ren Nutr; 2007 Jan; 17(1):48-52. PubMed ID: 17198932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein-bound uremic toxins: new culprits of cardiovascular events in chronic kidney disease patients.
    Ito S; Yoshida M
    Toxins (Basel); 2014 Feb; 6(2):665-78. PubMed ID: 24561478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deleterious vascular effects of indoxyl sulfate and reversal by oral adsorbent AST-120.
    Six I; Gross P; Rémond MC; Chillon JM; Poirot S; Drueke TB; Massy ZA
    Atherosclerosis; 2015 Nov; 243(1):248-56. PubMed ID: 26408929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indoxyl sulfate and progression of renal failure: effects of a low-protein diet and oral sorbent on indoxyl sulfate production in uremic rats and undialyzed uremic patients.
    Niwa T; Tsukushi S; Ise M; Miyazaki T; Tsubakihara Y; Owada A; Shiigai T
    Miner Electrolyte Metab; 1997; 23(3-6):179-84. PubMed ID: 9387112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indoxyl sulfate is a nephro-vascular toxin.
    Niwa T
    J Ren Nutr; 2010 Sep; 20(5 Suppl):S2-6. PubMed ID: 20797565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients.
    Niwa T; Nomura T; Sugiyama S; Miyazaki T; Tsukushi S; Tsutsui S
    Kidney Int Suppl; 1997 Nov; 62():S23-8. PubMed ID: 9350673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of AST-120 on blood concentrations of protein-bound uremic toxins and biomarkers of cardiovascular risk in chronic dialysis patients.
    Lee CT; Hsu CY; Tain YL; Ng HY; Cheng BC; Yang CC; Wu CH; Chiou TT; Lee YT; Liao SC
    Blood Purif; 2014; 37(1):76-83. PubMed ID: 24576840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New oral spherical carbon adsorbent effectively reduces serum indoxyl sulfate levels in moderate to advanced chronic kidney disease patients: a multicenter, prospective, open-label study.
    Kim SH; Jhee JH; Choi HY; Lee SH; Shin SK; Lee SY; Yang DH; Yi JH; Han SW; Jo YI; Park HC
    BMC Nephrol; 2020 Jul; 21(1):317. PubMed ID: 32736531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Different Types of Oral Adsorbent Therapy in Patients with Chronic Kidney Disease: A Multicenter, Randomized, Phase IV Clinical Trial.
    Kee YK; Han SY; Kang DH; Noh JW; Jeong KH; Kim GH; Kim YW; Kim BS
    Yonsei Med J; 2021 Jan; 62(1):41-49. PubMed ID: 33381933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for progression of chronic kidney disease in the EPPIC trials and the effect of AST-120.
    Schulman G; Berl T; Beck GJ; Remuzzi G; Ritz E; Shimizu M; Kikuchi M; Shobu Y
    Clin Exp Nephrol; 2018 Apr; 22(2):299-308. PubMed ID: 28741050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A metabolomic approach to clarifying the effect of AST-120 on 5/6 nephrectomized rats by capillary electrophoresis with mass spectrometry (CE-MS).
    Akiyama Y; Takeuchi Y; Kikuchi K; Mishima E; Yamamoto Y; Suzuki C; Toyohara T; Suzuki T; Hozawa A; Ito S; Soga T; Abe T
    Toxins (Basel); 2012 Nov; 4(11):1309-22. PubMed ID: 23202318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uremic toxicity of indoxyl sulfate.
    Niwa T
    Nagoya J Med Sci; 2010 Feb; 72(1-2):1-11. PubMed ID: 20229698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.